Evaluating E. coli JW0387 for scalable, universal AAV transfer plasmid amplification

Can a single plasmid amplification workflow support every AAV program?

Maintaining inverted terminal repeat (ITR) integrity during plasmid amplification remains one of the persistent challenges in AAV manufacturing. Even small changes in ITR structure can influence downstream vector production, making plasmid quality a critical consideration when scaling gene therapy workflows.

In this study, Revvity scientists evaluated the E. coli JW0387 strain as a potential universal solution for transfer plasmid amplification across diverse AAV constructs. Rather than optimizing bacterial strains for individual plasmids, the goal was to determine whether a single scalable workflow could reliably support hundreds of different transfer plasmids while preserving ITR fidelity.

Using automated plasmid characterization with the LabChip™ GXII Touch system together with long-read sequencing and downstream AAV production analyses, the team compared JW0387 with commonly used bacterial strains across multiple culture conditions.

The results demonstrate that while JW0387 maintained upstream productivity and full capsid generation comparable to standard strains, it also showed improved preservation of ITR integrity—an important consideration for robust AAV manufacturing workflows. The study also highlights how automated plasmid quality assessment can provide valuable insight into plasmid topology and sequence stability during process development.

Download the poster to explore:

• Evaluation of JW0387 as a universal strain for AAV transfer plasmid amplification
• Automated plasmid topology analysis using the LabChip™ GXII Touch system
• Long-read sequencing approach for assessing ITR integrity
• Comparison of plasmid yield, vector productivity and full capsid generation
• Considerations for scalable molecular biology workflows supporting AAV manufacturing

For research use only. Not for use in diagnostic procedures. A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.